{
    "2018-12-21": [
        [
            {
                "time": "2018-12-21",
                "original_text": "Novartis Enters Oversold Territory (NVS)",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Oversold",
                        "Territory"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-21",
                "original_text": "Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug",
                "features": {
                    "keywords": [
                        "Gene",
                        "Therapy",
                        "Cost",
                        "Effective",
                        "Biogen"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-21",
                "original_text": "Pfizer and GlaxoSmithKlineâ€™s Joint Venture: What to Expect",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "GlaxoSmithKline",
                        "Joint",
                        "Venture"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-21",
                "original_text": "Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Offers",
                        "Buy",
                        "French",
                        "Gene",
                        "Therapy",
                        "Manufacturer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-21",
                "original_text": "Pre-Market Most Active for Dec 21, 2018 : NVS, AFL, NBR, GNW, AMD, SQQQ, TQQQ, KBR, QQQ, FOXA, NIO, VOD",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Most",
                        "Active",
                        "NVS",
                        "AFL",
                        "NBR",
                        "GNW",
                        "AMD",
                        "SQQQ",
                        "TQQQ",
                        "KBR",
                        "QQQ",
                        "FOXA",
                        "NIO",
                        "VOD"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diverse"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-21",
                "original_text": "U.S body says gene therapy may be more cost effective for spinal muscular atrophy",
                "features": {
                    "keywords": [
                        "U.S",
                        "body",
                        "gene",
                        "therapy",
                        "cost",
                        "effective",
                        "spinal",
                        "muscular",
                        "atrophy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}